Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 174.9%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 98,700 shares, a growth of 174.9% from the September 15th total of 35,900 shares. Currently, 2.8% of the company’s shares are short sold. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is presently 0.1 days.

Windtree Therapeutics Stock Up 1.9 %

WINT opened at $0.72 on Friday. The stock has a market cap of $421,850.00, a PE ratio of -0.03 and a beta of 0.55. Windtree Therapeutics has a twelve month low of $0.69 and a twelve month high of $27.00. The company has a fifty day moving average of $5.85 and a 200-day moving average of $5.11.

Windtree Therapeutics (NASDAQ:WINT) last posted its quarterly earnings data on Monday, August 19th. The company reported ($20.91) earnings per share for the quarter, missing the consensus estimate of ($8.11) by ($12.80). Sell-side analysts anticipate that Windtree Therapeutics will post -2.38 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.